Prophylaxis and Treatment of Pregnant Women for Emerging Infections and Bioterrorism Emergencies
Open Access
- 1 November 2006
- journal article
- review article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 12 (11) , 1631-1637
- https://doi.org/10.3201/eid1211.060618
Abstract
Emerging infectious disease outbreaks and bioterrorism attacks warrant urgent public health and medical responses. Response plans for these events may include use of medications and vaccines for which the effects on pregnant women and fetuses are unknown. Healthcare providers must be able to discuss the benefits and risks of these interventions with their pregnant patients. Recent experiences with outbreaks of severe acute respiratory syndrome, monkeypox, and anthrax, as well as response planning for bioterrorism and pandemic influenza, illustrate the challenges of making recommendations about treatment and prophylaxis for pregnant women. Understanding the physiology of pregnancy, the factors that influence the teratogenic potential of medications and vaccines, and the infection control measures that may stop an outbreak will aid planners in making recommendations for care of pregnant women during large-scale infectious disease emergencies.Keywords
This publication has 37 references indexed in Scilit:
- Utilization of Animal Studies to Determine the Effects and Human Risks of Environmental Toxicants (Drugs, Chemicals, and Physical Agents)Pediatrics, 2004
- The Role of the Obstetrician–Gynecologist in Emerging Infectious Diseases: Monkeypox and PregnancyObstetrics & Gynecology, 2004
- Safety profile of quinolone antibiotics in the pediatric populationThe Pediatric Infectious Disease Journal, 2003
- Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003.2003
- Information on medication use in pregnancy.2003
- Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).2003
- Smallpox vaccination and adverse reactions. Guidance for clinicians.2003
- Developmental toxicity of ribavirin/IFα combination therapy: Is the label more dangerous than the drugs?Birth Defects Research Part A: Clinical and Molecular Teratology, 2003
- Teratogenicity of recently introduced medications in human pregnancyObstetrics & Gynecology, 2002
- Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks?American Journal of Obstetrics and Gynecology, 2002